Update on pulmonary arterial hypertension research: proceedings from a meeting of experts

Vallerie McLaughlin, Matthew Bacchetta, David Badesch, Raymond Benza, Charles Dwayne Burger, Kelly Chin, Robert Frantz, Adaani Frost, Anna Hemnes, Nick H. Kim, Erika B. Rosenzweig, Lewis Rubin

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: While pulmonary arterial hypertension (PAH) remains a progressive, symptomatic condition characterized by increased pulmonary vascular resistance, ultimately leading to right heart failure, great strides have been made in its understanding and treatment over the past two decades. Review: Continued research in pre-clinical, clinical, and health economic areas of research, in addition to registry analyses and technology advances, is critical for understanding the pathophysiology of the disease and devising the best ways to monitor and manage patients. On December 3, 2016, the latest pre-clinical, clinical, health economic outcome, and registry data on PAH was presented in a symposium sponsored by Actelion. This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting.

Original languageEnglish (US)
Pages (from-to)263-273
Number of pages11
JournalCurrent Medical Research and Opinion
Volume34
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Pulmonary Hypertension
Research
Registries
Economics
Health
Vascular Resistance
Heart Failure
Technology
Therapeutics

Keywords

  • Clinical
  • health economics
  • preclinical
  • proceedings
  • pulmonary arterial hypertension
  • registry
  • technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Update on pulmonary arterial hypertension research : proceedings from a meeting of experts. / McLaughlin, Vallerie; Bacchetta, Matthew; Badesch, David; Benza, Raymond; Burger, Charles Dwayne; Chin, Kelly; Frantz, Robert; Frost, Adaani; Hemnes, Anna; Kim, Nick H.; Rosenzweig, Erika B.; Rubin, Lewis.

In: Current Medical Research and Opinion, Vol. 34, No. 2, 01.02.2018, p. 263-273.

Research output: Contribution to journalReview article

McLaughlin, V, Bacchetta, M, Badesch, D, Benza, R, Burger, CD, Chin, K, Frantz, R, Frost, A, Hemnes, A, Kim, NH, Rosenzweig, EB & Rubin, L 2018, 'Update on pulmonary arterial hypertension research: proceedings from a meeting of experts', Current Medical Research and Opinion, vol. 34, no. 2, pp. 263-273. https://doi.org/10.1080/03007995.2017.1404974
McLaughlin, Vallerie ; Bacchetta, Matthew ; Badesch, David ; Benza, Raymond ; Burger, Charles Dwayne ; Chin, Kelly ; Frantz, Robert ; Frost, Adaani ; Hemnes, Anna ; Kim, Nick H. ; Rosenzweig, Erika B. ; Rubin, Lewis. / Update on pulmonary arterial hypertension research : proceedings from a meeting of experts. In: Current Medical Research and Opinion. 2018 ; Vol. 34, No. 2. pp. 263-273.
@article{fab0baa7728f4fa0befbd4fd2b82afa1,
title = "Update on pulmonary arterial hypertension research: proceedings from a meeting of experts",
abstract = "Background: While pulmonary arterial hypertension (PAH) remains a progressive, symptomatic condition characterized by increased pulmonary vascular resistance, ultimately leading to right heart failure, great strides have been made in its understanding and treatment over the past two decades. Review: Continued research in pre-clinical, clinical, and health economic areas of research, in addition to registry analyses and technology advances, is critical for understanding the pathophysiology of the disease and devising the best ways to monitor and manage patients. On December 3, 2016, the latest pre-clinical, clinical, health economic outcome, and registry data on PAH was presented in a symposium sponsored by Actelion. This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting.",
keywords = "Clinical, health economics, preclinical, proceedings, pulmonary arterial hypertension, registry, technology",
author = "Vallerie McLaughlin and Matthew Bacchetta and David Badesch and Raymond Benza and Burger, {Charles Dwayne} and Kelly Chin and Robert Frantz and Adaani Frost and Anna Hemnes and Kim, {Nick H.} and Rosenzweig, {Erika B.} and Lewis Rubin",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/03007995.2017.1404974",
language = "English (US)",
volume = "34",
pages = "263--273",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Update on pulmonary arterial hypertension research

T2 - proceedings from a meeting of experts

AU - McLaughlin, Vallerie

AU - Bacchetta, Matthew

AU - Badesch, David

AU - Benza, Raymond

AU - Burger, Charles Dwayne

AU - Chin, Kelly

AU - Frantz, Robert

AU - Frost, Adaani

AU - Hemnes, Anna

AU - Kim, Nick H.

AU - Rosenzweig, Erika B.

AU - Rubin, Lewis

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background: While pulmonary arterial hypertension (PAH) remains a progressive, symptomatic condition characterized by increased pulmonary vascular resistance, ultimately leading to right heart failure, great strides have been made in its understanding and treatment over the past two decades. Review: Continued research in pre-clinical, clinical, and health economic areas of research, in addition to registry analyses and technology advances, is critical for understanding the pathophysiology of the disease and devising the best ways to monitor and manage patients. On December 3, 2016, the latest pre-clinical, clinical, health economic outcome, and registry data on PAH was presented in a symposium sponsored by Actelion. This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting.

AB - Background: While pulmonary arterial hypertension (PAH) remains a progressive, symptomatic condition characterized by increased pulmonary vascular resistance, ultimately leading to right heart failure, great strides have been made in its understanding and treatment over the past two decades. Review: Continued research in pre-clinical, clinical, and health economic areas of research, in addition to registry analyses and technology advances, is critical for understanding the pathophysiology of the disease and devising the best ways to monitor and manage patients. On December 3, 2016, the latest pre-clinical, clinical, health economic outcome, and registry data on PAH was presented in a symposium sponsored by Actelion. This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting.

KW - Clinical

KW - health economics

KW - preclinical

KW - proceedings

KW - pulmonary arterial hypertension

KW - registry

KW - technology

UR - http://www.scopus.com/inward/record.url?scp=85041052135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041052135&partnerID=8YFLogxK

U2 - 10.1080/03007995.2017.1404974

DO - 10.1080/03007995.2017.1404974

M3 - Review article

C2 - 29132217

AN - SCOPUS:85041052135

VL - 34

SP - 263

EP - 273

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -